Nothofagin (cas 11023-94-2) suppresses mast cell-mediated allergic inflammation

Add time:08/16/2019    Source:sciencedirect.com

Mast cells play a major role in immunoglobulin E-mediated allergic inflammation, which is involved in asthma, atopic dermatitis, and allergic rhinitis. Nothofagin (cas 11023-94-2) has been shown to ameliorate various inflammatory responses such as the septic response and vascular inflammation. In this study, we assessed the inhibitory effect of nothofagin on allergic inflammation using cultured/isolated mast cells and an anaphylaxis mouse model. Nothofagin treatment prevented histamine and β-hexosaminidase release by reducing the influx of calcium into the cytosol in a concentration-dependent manner. Nothofagin also inhibited the gene expression and secretion of pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin-4 by downregulating the phosphorylation of Lyn, Syk, Akt and nuclear translocation of nuclear factor-κB. To confirm these effects of nothofagin in vivo, we used a passive cutaneous anaphylaxis mouse model. Topical administration of nothofagin suppressed local pigmentation and ear thickness. Taken together, these results suggest nothofagin as a potential candidate for the treatment of mast cell-involved allergic inflammatory diseases.

We also recommend Trading Suppliers and Manufacturers of Nothofagin (cas 11023-94-2). Pls Click Website Link as below: cas 11023-94-2 suppliers

Prev:Council classifies lincomycin hydrochloride (Lincocin) in Group B
Next:Original articleRenal protective effects of aspalathin and Nothofagin (cas 11023-94-2) from rooibos (Aspalathus linearis) in a mouse model of sepsis)